Immunohistochemical analysis of cyclooxygenase-2 and XXXX in pancreaticobiliary maljunction.

@entity1 @entity32 @entity7 @entity5 @entity1373 @entity2247 @entity1141
Recent studies have elucidated that @entity2247 is strongly related to @entity5 progression or development by means of its anti-apoptotic effect, enhancement of angiogenesis or decrease of cell-to-cell adhesive activity. However, there is no report on the relationship between @entity2247 expression and angiogenesis in pancreaticobiliary maljunction (PBM). We examined the correlation between the overexpression of @entity2247 and @entity7 ( @entity7 ) in 65 lesions from 30 @entity1 with PBM immunohistochemically. The positive expression of @entity2247 was found in 20% of regenerative epithelium, 11.1% of @entity1373 without atypia, 86.4% of @entity1373 with mild atypia, 75% of @entity1141 , and 75% of @entity5 . @entity7 was highly expressed in 80% of regenerative epithelium, 27.8% of @entity1373 without atypia, 86.4% of @entity1373 with mild atypia, 66.7% of @entity1141 , and 75% of @entity5 . The positive rate of both @entity2247 and VEFG expression was significantly higher in @entity1373 with atypia, @entity1141 and @entity5 than that in @entity1373 without atypia. In addition, there was a statistically significant correlation between @entity2247 and @entity7 overexpression among all lesions. In 6 of 8 @entity1 of various histological types, both @entity2247 and @entity7 were stained in almost exactly the same locations. In addition, there were no significant differences between the degree of @entity32 in the surrounding stroma and the expression of @entity2247 and @entity7 , respectively. These results demonstrated a strong relationship between @entity2247 and @entity7 overexpression in PBM. Therefore, chemoprevention via the suppression of angiogenesis by means of @entity2247 inhibitor may be effective in PBM.
